Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
KRAS G12C-mutant colorectal cancer
What changed

KRAS G12C-mutant colorectal cancer

What changed: KRAS G12C-mutant colorectal cancer

Cancer page →

Every dated change on the records linked to KRAS G12C-mutant colorectal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Approval2Regulatory2Trial result4Milestone7This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordKRAS G12C-mutant colorectal cancer
Facts on this page last checked
When this page itself was last checked or edited.

January 2025 · 1

2025-01-16RegulatorySotorasib
Sotorasib: approval (US)
KRAS G12C colorectal cancer with panitumumab (CodeBreaK 300)

2025 · 2

2025ApprovalSotorasib
Sotorasib approved in US
KRAS G12C colorectal cancer with panitumumab
2025MilestoneSotorasib
FDA approves sotorasib with panitumumab
A milestone in how this cancer is treated.

June 2024 · 1

2024-06-21RegulatoryAdagrasib
Adagrasib: approval (US)
KRAS G12C colorectal cancer with cetuximab (accelerated)

2024 · 2

2024ApprovalAdagrasib
Adagrasib approved in US
KRAS G12C colorectal cancer with cetuximab
2024MilestoneAdagrasib
FDA accelerated approval of adagrasib with cetuximab
A milestone in how this cancer is treated.

2023 · 5

2023Trial resultCodeBreaK 300
CodeBreaK 300 reported
PFS HR 0.
2023Trial resultFRESCO-2
FRESCO-2 reported
OS 7.
2023Trial resultPhase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 reported
Pancreatic cancer cohort: objective response in 7 of 21 patients (33.
2023Trial resultSUNLIGHT
SUNLIGHT reported
OS 10.
2023MilestonePhase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
KRYSTAL-1 and CodeBreaK 300 show that adding an anti-EGFR antibody makes KRAS G12C inhibitors work in the bowel
A milestone in how this cancer is treated.

2021 · 1

2021MilestoneSotorasib
Sotorasib becomes the first approved KRAS inhibitor (lung cancer)
A milestone in how this cancer is treated.

2013 · 1

2013MilestoneKRAS
Ostrem and Shokat describe covalent inhibitors of KRAS G12C
A milestone in how this cancer is treated.

2008 · 1

2008MilestoneCetuximab
KRAS mutations shown to predict failure of cetuximab and panitumumab
A milestone in how this cancer is treated.

1982 · 1

1982MilestoneKRAS
KRAS identified as a human oncogene
A milestone in how this cancer is treated.